Hemostatic variables ,carbohydrate metabolism and lipid profile in women with low body mass index

References

• Salonen EM, Saksela O, Vartio T, et al. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem 1985;260: 12302–7
   PubMed Web of Science ®Google Scholar
• Werb Z, Mainardi CL, Vater CA, et al. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017–23
   PubMed Web of Science ®Google Scholar
• Saksela O, Rifkin DB. Release of basic fibroblast growth factor—heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990; 110:767–75
   PubMed Web of Science ®Google Scholar
• Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med 1998;8: 923–38
   Google Scholar
• Stefansson S, Lawrence DA. The serpin PAT-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (London) 1996;383:441–3
   PubMed Web of Science ®Google Scholar
• Gebara OCE, Murray A, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham OfEpring Study. Circulation 1995;91:1952–8
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Plu-Bureau G, Bara L, et al. Hemostatic variables and menopausal status: influence ofhormone therapy. Thromb Hemost 1993;70:584–7
   PubMed Web of Science ®Google Scholar
• LoskutoffDJ, Samad F. The adipocyte and hemostatic balance in obesity. Arterioscler Thromb Vasc Biol 1988;18:1–16
   Google Scholar
• Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAT-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 1996;2:800–3
   PubMed Web of Science ®Google Scholar
• Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardio-vascular disease and death. Br MedJ1984;288:1401–4
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994;107:239–46
   PubMed Web of Science ®Google Scholar
• Vague P, Juhan-Vague I, Chabert V, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1989;38:913–15
   PubMed Web of Science ®Google Scholar
• Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism 1990;39:1044–8
   PubMed Web of Science ®Google Scholar
• Targher G, Tonoli M, Agostino G, et al. Ultra-sono graphic intra-abdominal depth and its relation to hemostatic factors in healthy males. Int J Obes 1996; 20:882–5
   Web of Science ®Google Scholar
• Cigolini M, Targher G, Bergamo AIA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arteriosder Thromb Vasc Biol 1996;16:368–74
   PubMed Web of Science ®Google Scholar
• Calles-Escandon J, Bailor D, Harvey-Berino J, et al. Amelioration of the inhibition of fibrinolysis in of basic fibroblastcomplexes fromactivator-mediated restriction. Am J Clin Nutr 1996;64:7–11
   Google Scholar
• Bachmann FW. Fibrinolysis. In Verstraete M, Vermylen J, Lijnen HR, et al., eds. Thrombosis Haemostasis. Leuven, Belgium: Leuven University
   Google Scholar
• Meade TW, Ruddock V. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.
   Google Scholar
• Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860–7
   PubMed Web of Science ®Google Scholar
• Cigolini M, Targher G, Seidell JC, et al. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis 1994;106:139–47
   PubMed Web of Science ®Google Scholar
• Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250–3
   PubMed Web of Science ®Google Scholar
• Eriksson P, Reynisdottir S, Lonnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998;41:65–71
   PubMed Web of Science ®Google Scholar
• Morange PE, Aubert J, Peiretti F, et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999;48:890–5
   PubMed Web of Science ®Google Scholar
• Shimomura I, Takahashi M, TokunagaK, et al. Rapid enhancement of acyl-CoA synthetase, LPL, and GLUT-4 mRNAs in adipose tissue of VMH rats. Am J Physiol 1996;270:E995–1002
   PubMedGoogle Scholar
• Lundgren CH, Brown SL, Nordt TK, et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenic link between obesity and cardiovascular disease. Circulation 1996; 93:106–10
   Google Scholar
• Eriksson P, Harmelen VV, Hoffstedt J, et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Hemost 2000;83:545–8
   PubMed Web of Science ®Google Scholar
• Pertyriski T, Pola I, Cierniewska-Cieglak A, et al. Expression of PAT-1 in human visceral and sub-cutaneous fat and its correlation with blood plasma PAT-1 levels. 9th International Menopause Society World Congress on the Menopause, Yokohama, Japan, 17–21 October 1999:455–60
   Google Scholar
• Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasmino gen activator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest 1996; 97:37–46
   Google Scholar
• De Pergola G, De Mitrio V, Giorgino F, et al. Increase in both pro-thrombotic and antithrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes 1997;21:527–35
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Morange P, Renucci JF, et al. Fibrinogen, obesity and insulin resistance. Blood Coag Fibrinol 1999;10 (Suppl 1):S25–8
   Google Scholar
• Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996;10:127–36
   Google Scholar
• Bjorntop P. Endocrine abnormalities of obesity. Metabolism 1995;44:21–3
   PubMed Web of Science ®Google Scholar
• Nozaki T, Tamai H, Matsubayashi S. et al. Insulin response to intravenous glucose in patients with anorexia nervosa showing low insulin response to oral glucose. J Clin Endocrinol Metab 1994;79:217–22
   Google Scholar
• Casper RC. Carbohydrate metabolism and its regulatory hormones in anorexia nervosa. Psychiatry 1996;62:85–96
   Google Scholar